These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30658491)

  • 1. Toxin Neutralization Using Alternative Binding Proteins.
    Jenkins TP; Fryer T; Dehli RI; Jürgensen JA; Fuglsang-Madsen A; Føns S; Laustsen AH
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30658491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of Manufacturing for Recombinant Snakebite Antivenoms.
    Jenkins TP; Laustsen AH
    Front Bioeng Biotechnol; 2020; 8():703. PubMed ID: 32766215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative Immunization Strategies for Antivenom Development.
    Bermúdez-Méndez E; Fuglsang-Madsen A; Føns S; Lomonte B; Gutiérrez JM; Laustsen AH
    Toxins (Basel); 2018 Nov; 10(11):. PubMed ID: 30400220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims.
    Kini RM; Sidhu SS; Laustsen AH
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History of Envenoming Therapy and Current Perspectives.
    Pucca MB; Cerni FA; Janke R; Bermúdez-Méndez E; Ledsgaard L; Barbosa JE; Laustsen AH
    Front Immunol; 2019; 10():1598. PubMed ID: 31354735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering of single-domain antibodies for next-generation snakebite antivenoms.
    Fernandes CFC; Pereira SS; Luiz MB; Silva NKRL; Silva MCS; Marinho ACM; Fonseca MHG; Furtado GP; Trevizani R; Nicolete R; Soares AM; Zuliani JP; Stabeli RG
    Int J Biol Macromol; 2021 Aug; 185():240-250. PubMed ID: 34118288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of snakebite envenoming: Future perspectives.
    Hamza M; Knudsen C; Gnanathasan CA; Monteiro W; Lewin MR; Laustsen AH; Habib AG
    Toxicon X; 2021 Sep; 11():100079. PubMed ID: 34430847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria.
    Habib AG; Lamorde M; Dalhat MM; Habib ZG; Kuznik A
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e3381. PubMed ID: 25569252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa.
    Williams DJ; Gutiérrez JM; Calvete JJ; Wüster W; Ratanabanangkoon K; Paiva O; Brown NI; Casewell NR; Harrison RA; Rowley PD; O'Shea M; Jensen SD; Winkel KD; Warrell DA
    J Proteomics; 2011 Aug; 74(9):1735-67. PubMed ID: 21640209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?
    Laustsen AH; Johansen KH; Engmark M; Andersen MR
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005361. PubMed ID: 28158193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivenoms for the treatment of snakebite envenomings: the road ahead.
    Gutiérrez JM; León G; Burnouf T
    Biologicals; 2011 May; 39(3):129-42. PubMed ID: 21429763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Next Generation Snakebite Antivenoms.
    Knudsen C; Laustsen AH
    Trop Med Infect Dis; 2018 Apr; 3(2):. PubMed ID: 30274438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy.
    Laustsen AH; Engmark M; Milbo C; Johannesen J; Lomonte B; Gutiérrez JM; Lohse B
    Curr Pharm Des; 2016; 22(34):5270-5293. PubMed ID: 27339430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Equine IgG Antivenoms against Major Snake Groups in Mozambique.
    Guidolin FR; Caricati CP; Marcelino JR; da Silva WD
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004325. PubMed ID: 26730709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bites and stings from venomous animals: a global overview.
    White J
    Ther Drug Monit; 2000 Feb; 22(1):65-8. PubMed ID: 10688262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment for venom-induced consumption coagulopathy resulting from snakebite.
    Maduwage K; Isbister GK
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3220. PubMed ID: 25340841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization capacity of recombinant antivenoms based on monoclonal antibodies and nanobodies.
    Ljungars A; Laustsen AH
    Toxicon; 2023 Jan; 222():106991. PubMed ID: 36481349
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies.
    Laustsen AH; Karatt-Vellatt A; Masters EW; Arias AS; Pus U; Knudsen C; Oscoz S; Slavny P; Griffiths DT; Luther AM; Leah RA; Lindholm M; Lomonte B; Gutiérrez JM; McCafferty J
    Nat Commun; 2018 Oct; 9(1):3928. PubMed ID: 30279409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitfalls to avoid when using phage display for snake toxins.
    Laustsen AH; Lauridsen LP; Lomonte B; Andersen MR; Lohse B
    Toxicon; 2017 Feb; 126():79-89. PubMed ID: 28017694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Cross-Reactivity in Antivenom Research.
    Ledsgaard L; Jenkins TP; Davidsen K; Krause KE; Martos-Esteban A; Engmark M; Rørdam Andersen M; Lund O; Laustsen AH
    Toxins (Basel); 2018 Sep; 10(10):. PubMed ID: 30261694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.